New cell therapy aims to stop blood cancer relapse in tough-to-treat patients
NCT ID NCT07566585
First seen May 07, 2026 · Last updated May 07, 2026
Summary
This early-phase study tests a new cell therapy called BSB-2002 in adults with a specific form of acute myeloid leukemia (AML) that has returned or not responded to at least two prior treatments. The main goal is to check the safety of the therapy and see if it can prevent the cancer from coming back. About 19 participants will receive the treatment in a hospital setting.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for AML, ADULT RECURRENT are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Washington University at St Louis
RECRUITINGSt Louis, Missouri, 63110, United States
Conditions
Explore the condition pages connected to this study.